Nebulized enriched heparin to treat no critical patients with Sars-Cov-2: Triple-blind clinical trial.
Medicine (Baltimore)
; 100(51): e28288, 2021 Dec 23.
Article
in English
| MEDLINE | ID: covidwho-1591728
ABSTRACT
BACKGROUND:
Coronavirus disease 2019 (COVID-19) is a viral respiratory disease that spreads rapidly, reaching pandemic status, causing the collapse of numerous health systems, and a strong economic and social impact. The treatment so far has not been well established and there are several clinical trials testing known drugs that have antiviral activity, due to the urgency that the global situation imposes. Drugs with specific mechanisms of action can take years to be discovered, while vaccines may also take a long time to be widely distributed while new virus variants emerge. Thus, drug repositioning has been shown to be a good strategy for defining new therapeutic approaches. Studies of the effect of enriched heparin in the replication of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in vitro assays justify the advance for clinical tests. METHODS ANDANALYSIS:
A phase I/II triple-blind parallel clinical trial will be conducted. Fifty participants with radiological diagnosis of grade IIA pneumonia will be selected, which will be allocated in 2 arms. Participants allocated in Group 1 (placebo) will receive nebulized 0.9% saline. Participants allocated in Group 2 (intervention) will receive nebulized enriched heparin (2.5âmg/mL 0.9% saline). Both groups will receive the respective solutions on a 4/4âhour basis, for 7 days. The main outcomes of interest will be safety (absence of serious adverse events) and efficacy (measured by the viral load).Protocols will be filled on a daily basis, ranging from day 0 (diagnosis) until day 8.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Heparin
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Medicine (Baltimore)
Year:
2021
Document Type:
Article
Affiliation country:
Md.0000000000028288
Similar
MEDLINE
...
LILACS
LIS